Drug intelligence / Profile preview

PC-0112

Development stage: Preclinical
Lead developer: Changtai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

PC-0112 is a small molecule oral solution being developed by Changtai Pharmaceutical (also known as PharmaMax Corp) for the treatment of pediatric allergic rhinitis and urticaria. The drug is specifically formulated as an oral solution to improve ease of administration and patient compliance in pediatric populations. It is currently categorized within Changtai Pharmaceutical's respiratory and allergy pipeline. While the specific molecular target has not been publicly disclosed, the product is designed to address common allergic conditions in children.

Beyond the preview

Go deeper on PC-0112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-0112.

Explore the full profile